Subscribe to RSS
DOI: 10.1055/s-2005-873068
© Georg Thieme Verlag KG Stuttgart · New York
Clinical Impact of Interstitial Pneumonia Following Surgery for Lung Cancer
Serum KL-6 is an Indicator?Publication History
Received August 1, 2005
Publication Date:
02 June 2006 (online)
![](https://www.thieme-connect.de/media/thoracic/200604/lookinside/thumbnails/10.1055-s-2005-873068-1.jpg)
Abstract
Background: Operative morbidity in patients with lung cancer associated with perioperative interstitial pneumonia (IP) has emerged as a serious problem. Patients and Methods: We studied the clinical impact of perioperative related IP in 11 patients (IP group: 7 preoperative known, 4 acute onset) of 473 lung cancer patients who received a pulmonary resection. The IP group was compared to the remaining 462 patients (non-IP group). Demographic data, clinical presentation, and serum KL-6 levels were compared. Results: There were no differences in age, gender, type of surgery, and pulmonary function except for % DLco between the non-IP and IP groups. The IP group showed a higher in-hospital mortality (n = 2: 18.3 %) than that of the non-IP group (n = 3: 0.6 %) (p < 0.005). Seven patients with underlying IP with high KL-6 levels showed an uneventful recovery. Two patients with postoperative onset of acute IP had a fatal course associated with elevation of serum KL-6 levels. Conclusions: Postoperative development IP is a serious complication with high mortality, and serial measurement of KL-6 levels is useful to assess the activity of IP.
Key words
Lung cancer - interstitial pneumonia - acute interstitial pneumonia - adult respiratory distress syndrome (ARDS)
References
- 1 Kutlu C A, Williams E A, Evans T W, Pastorino U, Goldstraw P. Acute lung injury and acute respiratory syndrome after pulmonary resection. Ann Thorac Surg. 2000; 69 376-380
- 2 Wada H, Nakamura T, Nakamoto K, Maeda M, Watanabe Y. Thirty day operative mortality for thoracotomy in lung cancer. J Thorac Cardiovasc Surg. 1998; 115 70-73
- 3 Tanita T, Chida M, Hoshikawa Y. et al . Experience with fetal interstitial pneumonia after operation for lung cancer. J Cardiovasc Surg. 2001; 42 125-129
- 4 Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Recent results of postoperative mortality for surgical resections in lung cancer. Ann Thorac Surg. 2004; 78 999-1003
- 5 Gross T J, Hunninghake G W. Idiopathic pulmonary fibrosis. New Engl J Med. 2001; 345 517-525
- 6 Nicholson A G, Colby T V, du Bois R M, Hansell D M, Wells A U. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000; 162 2213-2217
- 7 Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000; 161 5-8
- 8 Matsushita H, Tanaka S, Saiki Y. et al . Lung cancer associated with usual interstitial pneumonia. Pathol Int. 1995; 45 925-932
- 9 Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exerbation in idiopathic pulmonary fibrosis: Analysis of clinical and pathologic findings in three cases. Chest. 1993; 103 1808-1812
- 10 Kumar P, Goldstraw P, Yamada K. et al . Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg. 2003; 125 1321-1327
- 11 Chiyo M, Sekine Y, Iwata T. et al . Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg. 2003; 126 1141-1146
- 12 Fujimoto T, Okazaki T, Matsukura T. et al . Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication?. Ann Thorac Surg. 2003; 76 1674-1679
- 13 Martinod E, Azorin J F, Sadoun D. et al . Surgical resection of lung cancer in patients with underlying interstitial lung disease. Ann Thorac Surg. 2002; 74 1004-1007
- 14 Bouros D, Nicholson A C, Polychronopoulos V, du Bois R M. Acute interstitial pneumonia. Eur Respir J. 2000; 15 412-418
- 15 Goto K, Kodama T, Sekine I. et al . Serum levels of KL‐6 are useful biomarkers for severe radiation pneumonitis. Lung Cancer. 2001; 34 141-148
- 16 Nakahara K, Monden Y, Ohno K, Maeda H, Kawashima Y. A method for predicting postoperative lung function and its relation to postoperative complications in patients with lung cancer. Ann Thorac Surg. 1985; 39 260-265
- 17 King T E, Costabel U, Cordier J F. et al . Idiopathic pulmonary diagnosis and treatment: International consensus statement. Am J Respir Crit Care Med. 2000; 161 646-664
- 18 Katzenstein A A, Myers J L. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998; 157 1301-1315
- 19 Kobayashi J, Kitamura S. KL‐6: A serum marker for interstitial pneumonia. Chest. 1995; 108 311-315
- 20 Sakuma T, Takahashi K, Ohya N, Usuda K, Handa M. Serum KL‐6, a novel mucin-like glycoprotein, as a indicator of intersitial pneumonitis following lobectomy. Surg Today. 1999; 29 121-128
- 21 Greene K E, King Jr T E, Kuroki Y. et al . Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002; 19 439-446
- 22 Daniil Z D, Gilchrist F C, Nicholson A G. et al . A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 1999; 160 899-905
- 23 Kawasaki H, Nagai K, Yoshida J, Nishimura M, Nishiwaki Y. Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol. 2002; 81 33-37
- 24 Sato H, Callister M EJ, Mumby S. et al . KL‐6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J. 2004; 23 142-145
- 25 Yaekashiwa M, Nakayama S, Ohnuma K. et al . Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study. Am J Respir Crit Care Med. 1997; 156 1937-1944
MD, PhD Shin-ichi Takeda
Toneyama National Hospital
Toneyama 5 - 1 - 1
Toyonaka 560-8552
Japan
Phone: + 81668532001
Fax: + 816 68 50 17 50
Email: stakeda@toneyama.hosp.go.jp